

Daniel L Gustafson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862300/publications.pdf>

Version: 2024-02-01

65
papers

2,187
citations

257429

24
h-index

233409

45
g-index

65
all docs

65
docs citations

65
times ranked

3675
citing authors

#	ARTICLE	IF	CITATIONS
1	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 662-676.	7.0	38
2	Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs. <i>American Journal of Veterinary Research</i> , 2022, 83, 86-94.	0.6	10
3	Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3943-3961.	6.4	3
4	Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. <i>Journal of Equine Veterinary Science</i> , 2022, 113, 103933.	0.9	11
5	PLASMA CONCENTRATION AND PHARMACODYNAMICS OF INTRAMUSCULAR ADMINISTRATION OF ALFAXALONE IN INDIAN PEA FOWL (PAVO CRISTATUS). <i>Journal of Zoo and Wildlife Medicine</i> , 2022, 53, 108-115.	0.6	2
6	Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 294-305.	2.5	14
7	Predicting chemosensitivity using drug perturbed gene dynamics. <i>BMC Bioinformatics</i> , 2021, 22, 15.	2.6	1
8	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). <i>Clinical Cancer Research</i> , 2021, 27, 2435-2441.	7.0	46
9	Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. <i>Clinical Cancer Research</i> , 2021, 27, 3005-3016.	7.0	26
10	Evaluation of Intra-Articular Amikacin Administration in an Equine Non-inflammatory Joint Model to Identify Effective Bactericidal Concentrations While Minimizing Cytotoxicity. <i>Frontiers in Veterinary Science</i> , 2021, 8, 676774.	2.2	5
11	Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 699-712.	2.3	0
12	Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 331-342.	2.5	4
13	Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (<i>Cavia Tj ETQq1 1 0.784314 µgBT /Ov	1.3	0
14	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. <i>Communications Biology</i> , 2021, 4, 1178.	4.4	10
15	Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease. <i>Journal of Feline Medicine and Surgery</i> , 2020, 22, 376-383.	1.6	11
16	Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 143-151.	1.8	5
17	Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs. <i>Journal of the American Animal Hospital Association</i> , 2020, 56, 206-214.	1.1	0
18	Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2020, 44, 552.	1.3	4

#	ARTICLE	IF	CITATIONS
19	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1598-1612.	4.1	19
20	<p>Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib</p>. Oncolytic Virotherapy, 2020, Volume 9, 17-29.	6.0	1
21	Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Research, 2020, 80, 2689-2702.	0.9	24
22	Cancer Cells Upregulate NRF2 Signaling to Adapt to Autophagy Inhibition. Developmental Cell, 2019, 50, 690-703.e6.	7.0	74
23	The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 588-592.	1.3	7
24	Drug Design Targeting T-Cell Factor-Driven Epithelialâ€Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. Journal of Medicinal Chemistry, 2019, 62, 10182-10203.	6.4	12
25	A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. BMC Medical Genomics, 2019, 12, 87.	1.5	10
26	Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing. Molecular Cancer Therapeutics, 2019, 18, 1460-1471.	4.1	24
27	Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Molecular Pharmacology, 2019, 96, 36-46.	2.3	22
28	Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metabolism and Disposition, 2019, 47, 257-268.	3.3	25
29	The fecal microbiome and serum concentrations of indoxyl sulfate and pâ€eresol sulfate in cats with chronic kidney disease. Journal of Veterinary Internal Medicine, 2019, 33, 662-669.	1.6	37
30	Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers. Veterinary and Comparative Oncology, 2019, 17, 147-154.	1.8	12
31	SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, 4506-4506.	1.6	26
32	Hydroxychloroquine Sensitivity in Human and Canine Cancer Cell Line Panels Reveals Potential Genetic Signatures of Autophagyâ€Dependence and Druggable Targets. FASEB Journal, 2019, 33, 509.3.	0.5	0
33	Targeting the ErbB/MAPK Signaling Cascade in Canine Bladder Cancer Cell Lines. FASEB Journal, 2019, 33, 509.2.	0.5	0
34	Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 447-459.	2.5	67
35	Canine sarcomas as a surrogate for the human disease. , 2018, 188, 80-96.		53
36	In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. Journal of Veterinary Internal Medicine, 2018, 32, 1951-1957.	1.6	11

#	ARTICLE	IF	CITATIONS
37	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5398-5407.	0.9	20
38	Assessment of Modeling Techniques and Feature Selection for Predicting Drug Response from Gene Expression Data for Cytotoxic Anticancer Agents. <i>FASEB Journal</i> , 2018, 32, 566.5.	0.5	0
39	Vinca Alkaloid Pharmacokinetics in the Context of a Physiologically-Based Murine Model. <i>FASEB Journal</i> , 2018, 32, 834.3.	0.5	0
40	Assessment of absorption of transdermal ondansetron in normal research cats. <i>Journal of Feline Medicine and Surgery</i> , 2017, 19, 1245-1248.	1.6	4
41	Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. <i>Journal of Feline Medicine and Surgery</i> , 2017, 19, 998-1006.	1.6	23
42	Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 282-293.	2.5	56
43	A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain. <i>European Journal of Pharmacology</i> , 2016, 784, 1-14.	3.5	4
44	Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. <i>BMC Bioinformatics</i> , 2016, 17, 93.	2.6	31
45	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	12.4	108
46	Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at 20°C and room temperature. <i>Veterinary Dermatology</i> , 2015, 26, 228.	1.2	9
47	Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. <i>Veterinary Anaesthesia and Analgesia</i> , 2015, 42, 472-483.	0.6	13
48	STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. <i>Cancer Research</i> , 2014, 74, 2579-2590.	0.9	155
49	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. <i>Autophagy</i> , 2014, 10, 1415-1425.	9.1	149
50	Autophagy and Cancer Therapy. <i>Molecular Pharmacology</i> , 2014, 85, 830-838.	2.3	268
51	Pharmacokinetics of sustained-release analgesics in mice. <i>Journal of the American Association for Laboratory Animal Science</i> , 2014, 53, 478-84.	1.2	47
52	Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 437-449.	1.8	15
53	Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 157-176.	1.8	40
54	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4149-4162.	7.0	61

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 349-360.	2.3	42
56	A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man. <i>Clinical Cancer Research</i> , 2007, 13, 2768-2776.	7.0	70
57	Continuous Low-Dose Oral Chemotherapy for Adjuvant Therapy of Splenic Hemangiosarcoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2007, 21, 764-769.	1.6	119
58	Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 179-188.	2.3	45
59	Tissue Distribution and Metabolism of the Tyrosine Kinase Inhibitor ZD6474 (Zactima) in Tumor-Bearing Nude Mice following Oral Dosing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 872-880.	2.5	25
60	P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 248-254.	2.3	32
61	Pharmacokinetics of combined doxorubicin and paclitaxel in mice. <i>Cancer Letters</i> , 2005, 220, 161-169.	7.2	66
62	Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 159-166.	2.3	57
63	Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1079-1086.	2.5	19
64	Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1488-1501.	3.3	84
65	Expression of human O6-methyl guanine methyl transferase (MGMT) in post replication repair (PRR) deficient CHO-UV-1 cells: Compensation for hypersensitivity to methylating and ethylating agents but not to mitomycin C. <i>Somatic Cell and Molecular Genetics</i> , 1997, 23, 9-17.	0.7	2